Market Overview

Morning Market Movers

Share:
Related NBIX
Benzinga's Top Initiations
Neurocrine Reports Added NBI-98854 Data Will Be Presented at APA Meeting
This Week In Pharma: What Can We Expect From Upcoming Phase 2 Data For Seres Therapeutics' C.Difficile And Neurocrine Biosciences' Tourette Drugs? (Seeking Alpha)
Related EPZM
6 Biggest Mid-Day Losers For Monday
Mid-Day Market Update: Crude Oil Rises 2.5%; Epizyme Shares Drop
Celgene Pays Through The Nose For A Hand In Immune Checkpoints (Seeking Alpha)

Neurocrine Biosciences (NASDAQ: NBIX) jumped 60.40% to $15.66 after the company reported positive results of VMAT2 inhibitor NBI-98854 in Kinect 2 study.

Epizyme (NASDAQ: EPZM) moved up 55.32% to $31.84 after the company reported two major milestone achievements. It announced the achievement of a proof of concept milestone in the EPZ-5676 DOT1L inhibitor clinical program.

Verso Paper (NYSE: VRS) rose 31.70% to $4.23 after the company announced its plans to acquire NewPage for $1.4 billion.

Stereotaxis (NASDAQ: STXS) shares jumped 19.26% to $4.77 after the company Stereotaxis completed the clinical trial of Vdrive with V-Loop.

Posted-In: market moversNews Intraday Update Markets Movers

 

Related Articles (NBIX + EPZM)

View Comments and Join the Discussion!